... (NYSE: KG) 11.5% HIGHER; today announced that it has ended a patent infringement lawsuit filed against CorePharma LLC in regards to its drug Skelaxin. ...
... (NYSE: KG) 11.5% HIGHER; today announced that it has ended a patent infringement lawsuit filed against CorePharma LLC in regards to its drug Skelaxin. ...
... with the Securities and Exchange Commission that it has terminated its patent infringement lawsuit against CorePharma over the muscle relaxant Skelaxin. ...
The drug maker surged 16.4% following the termination its patent-infringement lawsuit over the muscle-relaxant drug Skelaxin and an agreement to grant ...
all 35 news articles
2 granting CorePharma certain rights for an authorized generic version of the company's 800 mg Skelaxin product. King also said ending the lawsuit ...
2, King will grant Core a nonexclusive license to make and sell a 400 mg metaxalone product, in what amounts to a generic form of Skelaxin. ...
The company is cutting its work force by 20 percent to trim costs, but still faces challenges to its patent for muscle relaxant Skelaxin and greater generic ...
... NR NR -3% Fentanyl 9 13 NR 10% -52% Ambien 10 10 8 8% 8% Skelaxin 11 11 9 9% 24% Tramadol 12 12 15 -5% -2% Duragesic 13 9 5 11% 9% Cyclobenzaprine 14 15 ...
The company's top three products are blood pressure medication Altace, muscle relaxant Skelaxin, and Thrombin-JMI, a liquid used to control bleeding during ...